NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term CAMBRIDGE, Mass., June 24, 2024 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks